Adam Koppel

Adam Koppel, a Partner at Bain Capital Life Sciences, dives into the evolving landscape of private equity in biopharma. He outlines why traditional PE shied away from biotech and how the sector has matured to require large-scale investments. Koppel shares Bain’s unique approach to prioritizing deals and maintaining capital discipline, even as average check sizes soar. He discusses the sustainability of this trend, raising concerns over development costs and company proliferation, while remaining optimistic about private financings and IPO readiness.